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Abstract 
Cancer cells require extensive metabolic reprogramming in order to provide the 
bioenergetics and macromolecular precursors needed to sustain a malignant phenotype.  
Mutant KRAS is a driver oncogene that is well known for its ability to regulate the ERK 
and PI3K signaling pathways. However, it is now appreciated that KRAS can promote 
tumor growth via upregulation of anabolic metabolism. We recently showed that 
oncogenic KRAS promotes a gene expression program of de novo lipogenesis in non-
small cell lung cancer (NSCLC). To define the mechanism(s) responsible, we focused on 
the lipogenic transcription factor SREBP1. We observed that KRAS increases SREBP1 
expression and genetic knockdown of SREBP1 significantly inhibited cell proliferation of 
mutant KRAS-expressing cells. Unexpectedly, lipogenesis was not significantly altered in 
cells subject to SREBP1 knockdown. Carbon tracing metabolic studies showed a 
significant decrease in oxidative phosphorylation and RNA-seq data revealed a significant 
decrease in mitochondrial encoded subunits of the electron transport chain (ETC). Taken 
together, these data support a novel role, distinct from lipogenesis, of SREBP1 on 
mitochondrial function in mutant KRAS NSCLC. 
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INTRODUCTION 
KRAS is the most frequently mutated oncogene in lung adenocarcinoma, present 
in up to 30% of cases (1-3). Lung cancer patients with tumors harboring KRAS mutations 
are associated with a poor prognosis and resistance to therapy (4). While there are 
covalent KRASG12C specific inhibitors and KRAS-SOS interaction directed therapeutics 
currently in clinical trials, there are currently no successful anti-KRAS therapies (5, 6). 
Accumulating studies have highlighted a potential for mutant KRAS to rewire cellular 
metabolism to promote tumor development. Substantial evidence shows that metabolic 
reprogramming is essential for tumor initiation and progression (7, 8). The “Warburg 
effect” describes a propensity for cancer cells to increase glucose uptake and convert the 
majority to of it to lactate even in the presence of oxygen (9). Originally, this increase in 
aerobic glycolysis displayed by cancer cells was attributed to damaged mitochondria. 
However, it is now appreciated that mitochondria remain functional in many tumors. In 
fact, mitochondrial metabolism is essential for providing the energy and precursors of 
protein, DNA, and lipids needed for the increased growth in cancer cells (10, 11). Despite 
growing evidence for altered metabolism in KRAS mutant NSCLC, how KRAS drives 
these changes is not clearly understood. 
Sterol element binding regulatory proteins (SREBPs) are key transcription factors 
involved in regulating lipid homeostasis in all vertebrates (12). There are three SREBP 
isoforms in mammals: SREBP1a, SREBP1c, and SREBP2. SREBP1a and 1c are 
encoded by a single gene with alternative transcription start sites, whereas a separate 
gene encodes SREBP2. SREBP1c enhances expression of genes involved in fatty acid 
uptake and synthesis while SREBP1a enhances gene expression of all SREBP-
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responsive genes (12). SREBP2 preferentially facilitates expression of genes required for 
cholesterol synthesis although it can also enhance expression of genes involved in fatty 
acid synthesis through upregulation of the other SREBPs (13). Accumulating evidence 
suggests that SREBP1 is a critical link between oncogene signaling and metabolism in 
cancer (14-18). SREBP1’s ability to regulate fatty acid and cholesterol metabolism 
provides tumor cells with the energy, biomass, and reducing equivalents required for 
tumor growth and survival. Accordingly, several studies have reported on the capacity of 
SREBP1 to support tumor growth via increased fatty acid synthesis.  For example, Guo 
et al. reported that SREBP1 signaling is required for survival of mutant EGFR-expressing 
glioblastoma (19). Several other studies have highlighted the importance of SREBP1 in 
cancers such as pancreatic, prostate, and colorectal cancers (17, 18, 20). However, the 
role of SREBP1 in NSCLC is not clear.  
We recently showed that mutant KRAS promotes a transcriptional program of de 
novo lipogenesis in NSCLC (21). Furthermore, mutant KRAS-expressing cells and tumors 
were sensitized to the growth inhibitory effects of FASN inhibitors. This prompted us to 
determine exactly how KRAS was driving this lipogenic transcription program. Here we 
show a novel function for SREBP1 in mutant KRAS-expressing NSCLC distinct from 
lipogenesis. We demonstrate that mutant KRAS promotes SREBP1 expression via 
MEK1/2 signaling, and loss of SREBP1 decreases growth. Despite this reduction in 
growth, de novo lipogenesis was not significantly altered. Importantly, reduction of 
SREBP1 led to decreased expression of the mitochondrial encoded subunits of the ETC. 
This decrease in mitochondrial gene expression led to impaired mitochondrial metabolism 
as made evident by decreased oxidative phosphorylation. These results delineate a link 
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between mutant KRAS and SREBP1 as well as highlight a novel role for SREBP1 on 
mitochondrial function distinct from lipogenesis in NSCLC. 
RESULTS 
Oncogenic KRAS increases SREBP1 expression 
Mutant KRAS promotes a gene expression program, which drives de novo 
lipogenesis in non-small cell lung cancer (21, 22).  In order to identify the transcriptional 
mechanism(s) responsible, we examined cDNA microarray data from studies of lungs of 
wildtype and KrasLSLG12D mice and observed a significant increase in expression of 
SREBP1 in lung tumors compared to normal lung (21). To confirm the effect of mutant 
KRAS on SREBP1, we transfected HEK 293T cells with full-length (FL) SREBP1 and 
increasing doses of mutant KRASG12V. KRASG12V induced a dose dependent increase in 
SREBP1 protein expression (Figure 1a, left panel). Classically, SREBP1 is retained in 
the endoplasmic reticulum. Activation of lipid sensing programs promote the cleavage of 
SREBP1 (cleaved SREBP1) which can then travel to the nucleus to activate transcription 
of its lipogenic targets. Interestingly, cleaved SREBP1 protein levels did not increase 
relative to full-length SREBP1 levels (Figure 1a, right panel) suggesting mutant KRAS 
is not affecting SREBP1 cleavage. To assess whether this was a mutant KRAS-
dependent effect, we transfected 293T cells with SREBP1 and equal amounts of either 
KRASWT or KRASG12V. While KRASWT induced SREBP1 expression slightly, the effect 
was much less pronounced than with KRASG12V (Supplemental Figure 1a).  
Next, we investigated whether oncogenic KRAS was necessary to induce SREBP1 
expression in NSCLC cells. Knockdown of KRAS in KRAS mutant H23 and A549 cells  
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(1, 23) led to a reduction in SREBP1 gene expression (gene name: SREBF1)  compared 
to non-target (NT) controls (Figure 1b). SREBP1 protein levels were similarly reduced 
(Figure 1c). In order to determine if KRASMUT was sufficient to induce SREBP1 
expression, we ectopically over-expressed exogenous KRASG12V in NSCLC cells, H1437 
and H1703, which are wild-type for KRAS. Ectopic expression of mutant KRAS did not 
significantly alter SREBP1 mRNA expression (Supplemental Figure 1b-d) compared to 
vector controls. However, endogenous SREBP1 protein expression was increased 
(Figure 1d). Similarly, in patient lung adenocarcinomas (TCGA Provisional) KRAS 
mutation with significantly correlated with SREBF1 mRNA abundance (p=0.03; 566 
samples).  
In order to identify which SREBP1 isoform (SREBP1a or SREBP1c) is 
predominately expressed in our NSCLC cell lines, we in-vitro translated SREBP1a and 
SREBP1c from plasmid DNA and subjected the products to SDS-PAGE in parallel with 
protein lysates for H23, A549, H137, H1703 (Supplemental Figure 1e). SREBP1a is 24 
amino acids bigger than SREBP1c and they can be distinguished by size on a western 
blot. SREBP1c (hereafter referred to as simply SREBP1) appeared to be the predominant 
isoform in all four NSCLC cell lines. 
Given that ectopic-overexpression of KRASG12V was not able to increase SREBP1 
mRNA levels, we wanted to determine whether mutant KRAS was regulating SREBP1 
expression post-transcriptionally. We inhibited protein synthesis using cycloheximide 
(CHX) in H1703 cells expressing either mutant KRAS (KRASG12V) or empty vector 
(Vector). CHX treatment of H1703  decreased SREBP1 protein levels to a greater degree 
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in H1703 cells expressing KRASG12V (Figure 1e). Together these results suggest that 
oncogenic KRAS increases SREBP1 protein translation in NSCLC.  
Loss of SREBP1 decreases cell proliferation in mutant KRAS NSCLC  
Next, we sought to determine the role of SREBP1 on cell expansion in NSCLC. 
We generated KRAS mutant and KRAS wild-type NSCLC cell lines, which stably 
expressing lentiviral based NTshRNA or one of two different shRNAs targeting SREBP1, 
shSREBP1 # 1 and shSREBP1 # 2. We confirmed reduced expression of full length 
SREBP1 in shSREBP1-expressing cells by western blot (Figure 2a, left panel). 
Strikingly, loss of SREBP1 resulted in a marked reduction in cell proliferation of KRAS 
mutant cells. (Figure 2b-c). In contrast to mutant KRAS-expressing cells, SREBP1 
knockdown (Figure 2c) had no effect or enhanced the proliferation of  KRASWT-
expressing cells (Figure 2e and 2f). These data  suggest that SREBP1 plays an essential 
role in the proliferation of mutant KRAS-expressing NSCLC cells.  
Oncogenic KRAS regulates SREBP1 protein expression via MEK1/2 signaling 
Our data demonstrate that mutant KRAS increases SREBP1 expression in NSCLC 
and in turn, SREBP1 promotes growth in  mutant KRAS-expressing NSCLC cells. KRAS 
asserts many of its effects through the MEK/ERK pathway (24, 25). Previous studies 
showed that MEK/ERK regulate translation (26). Therefore, we treated 293T cells 
transfected with SREBP1 and KRAS with the MEK inhibitor AZD6244 (27-29). MEK 
inhibition greatly blunted the effect of KRAS on SREBP1 protein expression compared to 
vehicle control (Figure 3a). In contrast, MEK inhibition did not alter SREBP1 protein levels 
in 293T cells not expressing KRASG12V (Figure 3b). Given that MEK inhibition reduced 
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SREBP1 protein expression in a mutant KRAS preferential manner, we next sought to 
determine whether activation of the MEK/ERK pathway alone would suffice to increase 
SREBP1 protein levels. We transfected 293T cells with a constitutively active 
MEK1D218,D222 allele (MEKDD) or KRASG12V (30). MEKDD expression led to increased 
SREBP1 protein expression mimicking the effect of KRASG12V (Figure 3c).  To further 
confirm that KRASG12V is regulating SREBP1 protein expression through the MEK/ERK 
pathway in NSCLC, we compared the effect of AZD6244 on SREBP1 levels to KRAS 
knockdown in H23 and A549 cells. MEK inhibitor treatment led to a significant decrease 
in protein levels of SREBP1 comparable to KRAS  knockdown cells (Figure 3d). While 
the effect of knocking down KRAS on FL-SREBP1 was more striking in H23 than in A549, 
densitometry of A549 western blot confirms that MEK inhibition is decreasing SREBP1 
expression to a greater degree in the mutant KRAS expressing cells (Figure 3d bottom 
panel). Collectively, these data strongly suggest that mutant KRAS increases SREBP1 
protein expression via the MEK/ERK pathway.  
Knockdown of SREBP1 does not decrease lipogenesis in NSCLC  
SREBP1 is known to induce the expression of key lipogenic enzymes including 
ATP Citrate lyse (ACLY), Acetyl-CoA carboxylase (ACC), and Fatty Acid Synthase 
(FASN), which in turn, promote cell growth by providing fatty acids, which are essential 
for the synthesis of membranes, energy storage, and signaling in cancer cells (12, 16, 
31). Our lab has previously shown that mutant KRAS promotes the expression of these 
genes in NSCLC (21). We sought to determine whether SREBP1’s canonical role in 
lipogenesis might explain the decrease in cell proliferation observed following KRAS 
knockdown in KRASMUT-expressing cells. We began by examining the expression of 
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lipogenic genes in mutant KRAS cells with stable SREBP1 knockdown. Surprisingly, 
knockdown of SREBP1 did not cause a significant decrease in ACLY, ACACA1 (ACC) or 
FASN in H23 or A549 (Figure 4a-d). We next investigated the functional effect of 
SREBP1 knockdown on de novo lipogenesis by performing 13C stable isotope analysis to 
measure the incorporation of 13C glucose into palmitate, which requires ACLY, ACC and 
FASN (Figure 4e). 13C enrichment into palmitate was not reduced following SREBP1 
knockdown, demonstrating reduced SREBP1 levels neither altered lipogenic gene 
expression nor lipogenesis (Figure 4f-g).  We also measured total levels of palmitate and 
saw no significant difference in palmitate levels in SREBP1 knockdown cells compared 
to non-target controls (Figure 4h-i). Although SREBP2 preferentially activates expression 
of genes involved in cholesterol biosynthesis, it has been shown to activate expression 
of genes involved in fatty acid synthesis (32, 33). Importantly, we did not observe a 
compensatory increase in SREBF2 levels (Supplemental Figure 2c, left) to rescue de 
novo lipogenesis in shSREBP1 expressing cells. Finally, KRAS wild-type cells subject to 
stable SREBP1 knockdown did not exhibit altered lipogenic gene expression or de novo 
lipogenesis (Supplemental Figure 2). Together, these data argue that SREBP1 
maintains cell proliferation in mutant KRAS-expressing cells independent of its canonical 
role in lipogenesis.  
Loss of SREBP1 decreases mitochondrial-encoded electron transport chain (ETC) 
genes in mutant KRAS cells 
The lack of changes to lipogenic gene expression in SREBP1 knockdown cells 
prompted us to performed RNA-seq analysis in NTshRNA and SREBP1 knockdown cells.  
Strikingly, we observed significant decreases in mitochondrial-encoded –  but not nuclear-
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encoded – electron transport chain (ETC) genes (Figure 5a) and confirmed these findings 
by qRT-PCR (Figure 5b-e). Geneset enrichment analysis (GSEA) showed significant 
association (q<0.001) with TCA cycle and oxidative phosphorylation signatures (data not 
shown).  Protein levels for mitochondrial-encoded cytochrome c oxidase I (MT-CO1) were 
also reduced in H23 and A549 cells expressing shSREBP1, whereas protein levels for 
nuclear-encoded ATP5A did not change (Figure 5f). In contrast, SREBP1 knockdown in 
KRASWT cells resulted in only minor declines to mitochondrial-encoded ETC gene 
expression  in H1437 (Figure 5g) and significant increases in H1703 (Figure 5h). This 
suggests that SREBP1’s effect on mitochondrial gene expression might be facilitated by 
mutant KRAS.  
Loss of SREBP1 does not alter mitochondrial mass and slightly decreases copy 
number 
Our data suggested that SREBP1 plays a role in mitochondrial biology specifically 
in KRAS mutant NSCLC cells. Indeed, mitochondrial transcription factor A (TFAM), which 
is required for mitochondrial DNA replication and transcription (34, 35) was significantly 
reduced following SREBP1 knockdown in H23 and A549 (Figure 5i). To determine if the 
loss of ETC gene and protein expression was due in part to a decrease in number of 
mitochondria, we stained cells with Mitotracker Green, a cell permeable dye which 
localizes and binds to mitochondria. There was no difference in GFP intensity, quantified 
by flow cytometry, between NTshRNA control and shSREBP1 cells (Supplemental 
Figure 3a). To further confirm that reduced SREBP1 expression is not affecting 
mitochondrial number, we measured mitochondrial copy number relative to nuclear DNA 
using RT-PCR, as previously described (36). There was a ~17% decrease in 
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mitochondrial DNA copy number in SREBP1 knockdown cells compared to NTshRNA 
controls (Supplemental Figure 3b). Suggesting the decrease in mitochondrial gene 
transcription could be in part due to lower mitochondrial DNA content. Taken together, 
these data suggest that SREBP1 knockdown results in decreased expression of 
mitochondrial-encoded ETC genes and mitochondrial DNA copy number. Furthermore, 
there were no alterations to mitochondrial mass suggesting SREBP1 knockdown is 
affecting transcription not mitochondrial biogenesis. Lastly, nuclear encoded genes that 
make up subunits of the ETC do not significantly change, suggesting this is not due to 
SREBP1’s transcriptional activity in the nucleus. 
Loss of SREBP1 decreases oxidative phosphorylation in mutant KRAS-expressing 
NSCLC cells 
Given the effect of SREBP1 knockdown on mitochondrial ETC gene expression, 
we wanted to determine the effects on mitochondrial function. Knockdown of SREBP1 
resulted in a significant decrease in basal oxygen consumption rate (OCR) (~80%) and 
maximal respiration (~70%) (Figure 6a-c) compared to NTshRNA cells expressing 
mutant KRAS. In contrast, we did not see any difference in basal OCR in KRASWT cells 
(H1437) with stable knockdown of SREBP1 (Supplemental Figure 4a-b). A major fuel 
for oxidative phosphorylation via the TCA cycle is glucose. Therefore, we performed 13C 
glucose tracer analysis to determine whether SREBP1 knockdown alters glucose 
utilization by the TCA cycle. We measured enrichment of m+2 metabolites into the TCA, 
since they would be derived from labeled glucose (Figure 6d). We observed a significant 
decrease in m+2 citrate (~56%), fumarate (~43%), and malate (~40%) when SREBP1 
was knocked down in H23 cells (Figure 6e). By contrast, we did not see a significant 
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change in these metabolites in KRASWT cells (H1437) with SREBP1 knockdown (Figure 
6f). These data suggest that knockdown of SREBP1 impairs oxidative phosphorylation 
from glucose in mutant KRAS-expressing cells. 
Given the increased expression of SREBP1 in NSCLC, we examined the effect of 
SREBP1 transcript levels on overall survival in patients with lung adenocarcinoma using 
Kmplotter (37). Kmplotter is an online survival analysis software that allows for the meta-
analysis of patient data from an integrative lung cancer microarray database. Overall 
survival was significantly lower in patients with tumors that have high expression of 
SREBP1 (p<0.01) (Supplemental Figure 5). It is important to note however that the 
survival curve does not consider mutant KRAS expression. Nonetheless, these data 
suggest SREBP1 expression is negatively associated with survival in patients with lung 
adenocarcinoma. 
DISCUSSION  
Activating mutations of KRAS drive metabolic alterations that promote tumor 
growth in NSCLC (21, 22, 24, 38-41). However, the detailed molecular mechanisms by 
which KRAS regulates metabolism in NSCLC are not well understood.  Here, we report 
a novel role for SREBP1 distinct from lipogenesis in KRAS-expressing NSCLC. 
Oncogenic KRAS increases SREBP1 expression and loss of SREBP1 leads to decreased 
cell proliferation independent of its role in lipogenesis. Importantly, high SREBP1 
expression correlates with poor survival in patients with lung adenocarcinoma. Most 
interestingly, we report for the first time, to our knowledge, that loss of SREBP1 in mutant 
KRAS-expressing NSCLC leads to reduction of mitochondrial-encoded ETC subunits, 
resulting in deficient mitochondrial metabolism.  
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Mutant KRAS activates over a dozen downstream targets to assert its pro-
tumorigenic effects and the RAF/MEK/ERK pathway is among one of the most well-
characterized (15). In fact, many approaches to targeting mutant KRAS cancers involve 
the utilization of MEK/ERK inhibitors (27-29, 42-44). Our work revealed that KRAS 
regulates SREBP1 expression via MEK/ERK activation. MEK inhibition using AZD6244 
greatly reduced the effect of mutant KRAS on SREBP1 protein expression in 293T cells. 
Furthermore, activation of MEK pathway with constitutively active MEK1 mutant, MEKDD, 
was sufficient to increase SREBP1 protein expression. Similarly, MEK inhibition in 
NSCLC cells (H23 and A549) reduced SREBP1 levels similar to KRAS knockdown. 
Multiple ERK1/2 phosphorylation sites have been mapped on SREBP1 (45), and ERKs 
1/2 are the only known targets of MEKs 1/2, implicating ERK in mutant KRAS mediated 
regulation of SREBP1. Interestingly, mutant KRAS does not appear to regulate SREBP1 
cleavage, suggesting KRAS controls SREBP1 activity independent of cleavage. 
However, additional inhibitor studies need to be performed to fully elucidate the 
mechanism(s) responsible for KRAS regulation of SREBP1. Beyond characterizing 
ERK1/2 phosphorylation sites on SREBP1, further work should also include proteomic 
analysis to map out all major post-translational modifications on SREBP1 in the presence 
and absence of mutant KRAS.  
Our results support the notion that SREBP1 is important for mutant KRAS- 
expressing NSCLC cell viability (16-18, 46); however we were surprised to find that loss 
of SREBP1 did not significantly alter gene expression of classic lipogenic targets ACLY, 
ACACA1, and FASN (21). Furthermore, using 13C tracer analysis with GC/MS, we found 
that mutant KRAS-expressing NSCLC with reduced levels of SREBP1 could still make 
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sufficient levels of saturated fatty acids such as palmitate. Williams et al. showed that an 
essential requirement for SREBP1 is to maintain the ratio of monosaturated vs 
monounsaturated fatty acids (47). In their study, loss of SREBP1 did not lead to 
decreases in palmitate but instead a significant decrease in monounsaturated fatty acids 
such as oleate which ultimately resulted in lipotoxicity and cell death. However, these 
studies were carried out in glioma cells, which are not mutant KRAS dependent. 
Additionally, oleate levels did not decrease in our models when SREBP1 was knocked 
down (data not shown), suggesting an alternative mechanism for loss of cell proliferation.  
Earlier studies focused on SREBP1’s role in lipid homeostasis and regulation via 
cleavage in low-cholesterol environments (12, 14, 19, 48). Recently, however, multiple 
studies have unraveled novel roles for SREBP1 in unexpected pathways linked to 
diabetes, cancer, the immune system, and autophagy (15, 49-53). Using RNA-seq 
analysis, we discovered loss of SREBP1 resulted in decreased mitochondrial gene 
expression in NSCLC cells. Loss of SREBP1 also reduced protein levels of mitochondrial 
transcription factor A (TFAM), which is one of three key transcription factors required for 
mitochondrial DNA replication and transcription (34). Interestingly, the effect of SREBP1 
on TFAM appeared to be translational since we did not see a difference in TFAM 
transcript in our RNA-seq analysis of SREBP1-knockdown cells. This suggests that 
SREBP1 is playing a role downstream of TFAM transcription. Decreased mitochondrial 
gene expression resulted in impaired mitochondrial function characterized by reduced 
TCA cycle flux and oxygen consumption. It is not clear whether decreased proliferation in 
SREBP1 knockdown cells is due to SREBP1’s effects on the mitochondria. Furthermore, 
our work did not establish whether SREBP1’s effect on the mitochondria is strictly mutant 
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KRAS-dependent. While mutant KRAS expression was sufficient to enhance SREBP1’s 
effect on the mitochondria as shown by genetic knockdown and overexpression 
experiments, further studies are required to determine to what extent KRAS is important 
in SREBP1-mediated mitochondrial metabolism and transcription. Additionally, it remains 
to be seen whether other prominent oncogenes in lung cancer, such as mutant EGFR 
which also activates ERK1/2, similarly alter SREBP1 function. Our results also suggest 
an alternative pathway for KRAS mediated lipogenesis in NSCLC since loss of SREBP1 
showed no significant decrease in de novo lipogenesis. Further studies are required to 
illuminate how KRAS is regulating fatty acid synthesis which could potentially be via other 
lipogenic transcription factors implicated in cancer such as carbohydrate responsive 
element–binding protein (ChREBP) (54). Finally, the finding that SREBP1 plays a role in 
mitochondrial homeostasis presents a novel opportunity for targeted therapy in KRAS 
mutant lung cancers. 
Materials and Methods 
[13C] isotopomer analysis 
Cells were seeded in 6-cm culture dishes (800,000 cells per dish) overnight. The 
following day, cells were washed twice with warm 1X PBS, and medium was changed to 
RPMI with 10 mM [U-13C6] glucose (Cambridge Isotopes) as the only glucose source and 
10% dialyzed FBS and 2 mM glutamine for 6-16 hours.  
Lipid extraction and GCMS analysis: Cells were harvested in 0.9% NaCl and 
centrifuged at 10,000 RPM at 4°C. The pellet was re-suspended in 2:1 
chloroform:methanol. Before drying down under nitrogen, 50 nmoles of heptadecanoic 
acid was added to all samples as an internal control. Fatty acids were then saponified as 
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previously described (21). Following saponification, metabolites were dried down under 
nitrogen again and methylated with boron trifluoride (Sigma, 15716). Mass spectral data 
were obtained on an Agilent 7890B Gas Chromatograph coupled with an Agilent 5977A 
MDS. The settings were as follows: GC inlet 230 °C, transfer line 280 °C, MS source 230 
°C MS Quad 150 °C. An HP-5MS column (30 M length, 250 µm diameter, 0.25 µm film 
thickness) was used for fatty acid analysis and palmitate and its isotopomers were 
monitored at 270-286 m/z.  
TCA cycle metabolite extraction: Intermediate metabolites were harvested in 
80% methanol in water with 10 nmoles adonitol per sample as internal control. 
Metabolites were dried down under nitrogen and derivatized as previously described (55). 
In brief, cells were frozen and thawed three times, and centrifuged, and the supernatant 
was collected. The supernatant was then dried down and methoximated using MOX 
(Thermo Scientific, TS-45950) and derivatized with BSTFA (TCI, B3402). All metabolite 
data was analyzed using Mass Hunter and abundance corrected using ISOCOR.  
Analysis of SREBP1 expression 
Publicly available data from the The Cancer Genome Atlas (TCGA) were analyzed 
for SREBP1 expression in 720 lung tumors. Overall survival and the hazard ratio were 
graphed and calculated using an online tool called KmPlotter (37). All cases analyzed 
were adenocarcinomas. 
Cell culture and reagents 
All cells were purchased from American Type Culture Collection (Manassas, 
Virginia, United States) and cultured under recommended conditions. Specifically, H23, 
A549, H1437 and H1703 cells were cultured in Roswell Park Memorial Institute (RPMI) 
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1640 medium (Corning) and Beas-2B and 293T cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Corning). All media were supplemented with 10% 
fetal bovine serum (FBS) (Gemini) unless indicated. Delipidated media (DL) was RPMI 
media supplemented 10% delipidated FBS (Gemini). Cells were transfected using 
Attractene reagent as per manufacturer’s suggestions (QIAGEN). Plasmids used in all 
transfections are listed in Table 6.2. The cell lines were routinely tested for mycoplasma 
contamination (56). All cells were incubated at 37° C with 5% CO2. 
Genetic manipulation of KRAS in vitro. 
H1437, H1703, H858, and H1299 cells were tranduced with retrovirus expressing 
KrasG12V (pBabe KRASG12V) or either green fluorescent protein (GFP) vector control 
(pCMV-GFP) or empty vector (pMSCV-Puro) to serve as controls. Retrovirus was 
generated using CaP transfection into phoenix cell. Cells were transfected with 
expression vectors for vsv and gag-pol with the retroviral vector of interest. A549 and H23 
NSCLC cells were transduced with lentivirus expressing non-target short hairpin RNA 
(NTshRNA) pLKO (NTshRNA) or shRNA against Kras (shKRAS;TRCN0000033262, 
MilliporeSigma, Burlington, MA, USA). Lentivrus was prepared as described above. 
Following infection, cells were selected in puromycin (1 µg/ml) for one week to establish 
stable pools. 
Genetic manipulation of SREBP1 in vitro 
For stable SREBP1 knockdown, H23, A549, H1437 and H1703 cells were infected 
with non- target shRNA lentivirus (NTshRNA) or lentivirus with one of two different 
commercially available shRNAs against SREBP1 (shSREBP1 #1:TRCN0000020605, 
shSREBP1 #2: TRCN0000020607) (MilliporeSigma, Burlington, MA, USA). Following 
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infection with virus, H23, A549, and H1703 cells were selected in 1 µg/ml of puromycin. 
H1437 were selected in 2 µg/ml of puromycin. All cells were grown in indicated doses of 
puromycin for one week to establish stable pools.  
In vitro translation 
 In vitro translation of full-length SREBP1a and full-length SREBP1c was carried 
out using the TNT rabbit reticulocyte lysate translation kit (Promega, Wisconsin, USA) as 
per the manufacturer’s instructions. In brief, plasmids with the open reading frames of 
SREBP1c and SREBP1a were mixed separately with the components of the TNT rabbit 
reticulate lysate kit and incubated at 30°C for 90 mins. Following incubation, the product 
was diluted 1:5 in water and subjected to SDS-PAGE alongside lysates of H23, A549, 
H1437, and H1703 cells. 
Mitochondrial DNA copy number 
 Mitochondrial DNA copy number was measured as previously described (36). In 
brief, H23 cells expressing NTshRNA or shSREBP1 # 1 were seeded in triplicate in a 6-
well culture dish (Corning). Genomic DNA was isolated using a commercially available kit 
(Invitrogen, K182001) as per the manufacturer’s instructions. Isolated DNA was subjected 
to PCR using primers for nuclear DNA (B2M) or mitochondrial DNA (ND1). The relative 
mitochondrial DNA content was then determined as follows: 
a. ΔCT = (nuclear DNA CT – mito DNA CT) 
b. Relative mitochondrial DNA content = 2 × 2ΔCT 
 
Mitochondrial oxygen consumption 
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Oxygen consumption rates were measured using a Seahorse Bioenergetic Flux analyzer 
(XFe96). Basal respiration and ATP-coupled respiration, represented as OCR, were 
measured using a Mitochondrial Stress Test assay as per manufacturer’s instructions 
(Agilent, 103015-100).  
Proliferation studies 
Growth Curves: Cells were seeded into 6-well dishes (Corning) with an initial seeding 
density of 30,000-50,000 cells per well and counted on days indicated using a Countess 
Automated Cell Counter (Thermo Fisher Scientific, Waltham, MA, USA) cell automated 
countess (Invitrogen). For treatment with inhibitors, ROS, and nutrients, cells were treated 
the morning after plating and final counts were performed 3 days later. 
Real-time RT-PCR 
Total RNA was extracted from tumors and cells with the RNeasy Kit (Qiagen, 
Hilden, Germany). The reverse-transcription reaction was performed with a high-capacity 
cDNA Synthesis Kit (Applied Biosystems). Real-time quantitative PCR analyses of human 
genes were performed, as previously described (21). All primers used are listed in Table 
6.3. One of three housekeeping genes, 18s, HPRT, or β-ACTIN was used for 
normalization. 
RNAseq analysis 
RNAseq was performed by Novagene (Novagene Sacramento, CA). Illumina 
HiSeq RNA sequencing of triplicate FASTQ file reads passing Illumina purity filter were 
aligned using TopHat2 and Cufflinks, with statistical analysis performed by CuffDiff, 
generating files of normalized counts for detected genes and transcripts (UCSC hg38). 
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The Galaxy server at UCLA (galaxy.org) was used for FASTQ alignment and analysis 
(57). Aligned RNAs passing QC thresholds were used to calculate transcript abundance 
ratios followed by log2 linear scaling. Functional association with RNA abundance 
changes was assessed by gene set enrichment (GSEA). As expected, multiple signatures 
associated with mitochondrial function were significantly enriched with normalized 
enrichment score (NES) p value <0.05 and the false discovery rate (FDR) q value <0.05.  
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Figure Legends 
Figure 1: Oncogenic KRAS increases SREBP1: a) Protein expression for 293T cells 
transfected with full length (FL) SREBP1 in the presence or absence of increasing 
amounts of KRASG12V. Protein was harvested 48 hours after transfection and analyzed 
via western blotting for SREBP1 and loading control, β-ACTIN. Densitometry analysis of 
FL-SREBP1 vs cleaved SREBP1 protein increase. Blots were analyzed using ImageJ. 
Values for SREBP1 were normalized to ACTIN values. SREBP1 expression for b) mRNA 
and c) protein in H23 and A549 stably expressing either NTshRNA or shKRAS. N=3 per 
group. Bars represent mean ± SD.*** p  < 0.001. d) Protein expression for FL-SREBP1 
and cleaved SREBP1 in H1437 and H1703 expressing either control vector, or KRASG12V. 
Proteins were analyzed via western blotting. e) Protein expression for H1703 cells treated 
with vehicle control or 10 µM of cyclohexamide (CHX) for 1 or 3 hours (hr). Cells were 
expressing either vector control or KRASG12V. Proteins were analyzed via western 
blotting.   
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Figure 2: Loss of SREBP1 decreases cell proliferation in mutant KRAS-expressing 
NSCLC cells. a) SREBP1 protein expression for H23 (left), A549 (right) and f) H1437 
(left), H1703 (right). Cells expressed either NTshRNA or one of two shSREBP1. 
Proteins were analyzed via western blot analysis. Cell number for mutant KRAS-
expressing cells a) H23, b) A549 and KRASWT expressing cells c) H1437 d) H1703. H23 
were expressing either NTshRNA or one of two shRNAs against SREBP1; shSREBP1 
#1 or shSREBP1 #2. All other cells expressed either NTshRNA or shSREBP #2. Cells 
were seeded in 6 well plates on day 0 and counted on indicated days using an automatic 
cell counter. N=3 per group. Bars show ± SD. *p<0.05, ***p<0.005.  
 
Figure 3: Oncogenic KRAS regulates SREBP1 protein expression via MEK1/2 
signaling. a) Protein expression for 293T treated with 2.5 µM of MEK inhibitor, AZD6244, 
for 16 hours. 293T were transfected with either control vector or FL-SREBP1 in the 
presence or absence of KRASG12V, 24 hours prior to drug treatment. b) Protein expression 
for 293T transfected with FL-SREBP1 and treated with AZD6244. Cells were treated 24 
hours post transfections and collected 16 hours after treatment. c) Protein expression for 
293T cells transfected with FL-SREBP1 and either KRASG12V or MEKDD. d) Protein 
expression for H23 (left) and A549 (right) treated with 10 µM of AZD6244 for 16 hours. 
Cells were stably expressing either NTshRNA or shKRAS. e) densitometry of A549 
western blot from (d). FL-SREBP1 was normalized to ACTIN. Blots were analyzed using 
ImageJ. 
 
Figure 4: SREBP1 knockdown does not decrease de novo lipogenesis in mutant 
KRAS expressing NSCLC cells. Gene and protein expression for SREBP1 and its 
lipogenic targets ACLY, ACC, and FASN in a) H23, b) A549. Cells expressed either 
NTshRNA or one of two different shSREBP1. N=3 per group. Bars indicate mean ± SD. 
***P< 0.005. e) Schematic for 13C glucose tracer analysis on de novo lipogenesis. Total 
13C glucose labeled palmitate in f) H23, g) A549. Total palmitate levels in h) H23 i) A549 
cells. Palmitate was measured via GS/MS and total counts were normalized to protein 
concentration of cells on day of collection (µg/µl). Cells expressed NTshRNA or one of 
two different shSREBP1 for all metabolite tracing experiments. N=5 per group. Bars 
indicate mean ± SD. * p <0.05, ***P< 0.005. 
 
Figure 5: Loss of SREBP1 decreases expression of mitochondrial encoded ETC 
genes in mutant KRAS NSCLC cells.  a) RNA seq analysis for mitochondrial encoded 
and nuclear encoded mitochondrial proteins in H23 cells expressing either NTshRNA, 
shSREBP1 #1 or shSREBP1 #2. shSREBP1 values were normalized to their NTshRNA 
expressing controls. N=3 per group. ± SD.*q <0.05 **q<0.01. Gene for mitochondrial 
encoded ETC genes in b) H23, and c) A549 cells expressing either NTshRNA shSREBP1 
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#1 or shSREBP1 #2. N=3 per group. Bars indicate ±SD. *p< 0.05. Gene expression for 
nuclear encoded ETC genes in d) H23 and e) A549 cells expressing either NTshRNA or 
one of two different shSREBP1. N=3 per group. Bars indicate ±SD. *p< 0.05. f) Protein 
expression for H23 (left) and A549 (right) cells expressing either NTshRNA or shSREBP1 
#2. Proteins were analyzed via western blotting. Gene expression for mitochondrial 
encoded genes in KRASWT g) H1437 and h) H1703 cells expressing either NTshRNA or 
shSREBP1 #2. N=3 per group. Bars indicate ± SD. ** p <0.01.  
 
Figure 6: Loss of SREBP1 decreases oxidative phosphorylation in mutant KRAS-
expressing NSCLC cells. a) Representative mitochondria stress test performed on H23 
expressing NTshRNA or shSREBP1 #2. The stress test provides b) basal respiration and 
c) maximal respiration. OCR was measured using a Seahorse Bioenergetic Flux 
Analyzer. N≥10 per group. Bars indicate mean ± SE. ****p < 0.0001. d) Schematic of 
glucose utilization by the TCA cycle into m+2 intermediates. Relative amount of 13C 
labeled m+2 citrate, fumarate, and malate in e) H23 and f) H1437 cells. Cells expressed 
NTshRNA or one of two different shSREBP1. Cells were labeled with 13C [U6] glucose, 
and harvested after 6 hr, and analyzed by GC/MS for TCA cycle metabolites. N=5 per 
group. Bars indicate ± SD.  * p <0.01, ** p <0.001. 
 
Supplemental Figures 
Supplemental Figure 1: Oncogenic KRAS increases SREBP1 expression: a) Protein 
expression in 293T cells transfected with FL-SREBP1 in the presence of either KRASWT 
or KRASG12V. SREBP1 mRNA expression for b) 293T, c) H1437, and d) H1703 cells. 
Cells were expressing empty vector (Vector) or KRASG12V. N=3 per group. Bars indicate  
± SD. * p <0.01 e) Full length (FL) SREBP1a and SREBP1c were produced via in vitro 
translation and subjected to SDS-PAGE alongside lysates of H23, A549, H1437, and 
H1703 cells.  
Supplemental Figure 2: SREBP1 knockdown does not decrease lipogenesis in 
NSCLC. Gene and protein expression for SREBP1 and its lipogenic targets ACLY, ACC 
(gene name: ACACA1), and FASN in KRASWT expressing cells. a) H1437, b) H1703. 
Cells expressed either NTshRNA or shSREBP1 #2. N=3 per group. Bars indicate ± SD. 
c) SREBF2 gene expression for H23 (left) and A549 (right). Total 13C glucose labeled 
palmitate in d) H1437, e) H1703. Total palmitate levels in f) H1737, and g) H1703. 
Palmitate was measured via GS/MS and total counts were normalized to protein 
concentration of cells on day of collection (µg/µl). Cells expressed NTshRNA or 
shSREBP1 #2 for all metabolite tracing experiments. N=5 per group. Bars indicate mean 
± SD. * p <0.05, ***P< 0.005. 
Supplemental Figure 3: Loss of SREBP1 does not alter mitochondrial mass and 
slightly decreases copy number. a) Mean fluorescence intensity (M.F.I) of H23 cells 
stained with MitoTracker Green. Cells were stably expressing either NTshRNA or 
shSREBP1 #2. Fluorescence was measured via flow cytometry. b) Mitochondrial DNA 
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content relative to nuclear DNA content in H23 expressing either NTshRNA or shSREBP1 
#2. DNA was harvested and subjected to qRTPCR. AU= Abitrary units. N=3 per group. 
Bars indicate mean ± SD. 
 
Supplemental Figure 4: Loss of SREBP1 decreases oxidative phosphorylation in 
mutant KRAS NSCLC cells. a) Representative mitochondria stress performed on H1437 
cells expressing NTshRNA or shSREBP1 #2. Test provides b) Basal OCR. N≥10 per 
group. Bars indicate mean ± SE. OCR was measured using a Seahorse Bioenergetic Flux 
Analyzer.  
 
Supplemental Figure 5: High SREBP1 expression correlates with poor survival in 
LUAD patients: a) Kaplan-Meier analysis of an integrative lung cancer microarray 
database showing expression levels of SREBP1 transcript (red:high, black:low) and 
association with overall survival. Data obtained from Km-plotter website. *p<0.05. 
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Figure 1: Oncogenic KRAS increases SREBP1 expression
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Figure 2: Loss of SREBP1 decreases cell proliferation in mutant KRAS expressing NSCLC 
cells
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Figure 3: Oncogenic KRAS regulates SREBP1 protein expression via MEK1/2 signaling
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Figure 4: SREBP1 knockdown does not decrease lipogenesis in NSCLC
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Figure 5: Loss of SREBP1 decreases mitochondrial-encoded electron transport chain (ETC) 
genes in mutant KRAS NSCLC cells 
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Figure 6: Loss of SREBP1 decreases oxidative phosphorylation in mutant KRAS NSCLC 
cells 
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